Zobrazeno 1 - 10
of 122
pro vyhledávání: '"Marjolein S. de Bruin‐Weller"'
Autor:
Eric L. Simpson, Vimal H. Prajapati, Yael A. Leshem, Raj Chovatiya, Marjolein S. de Bruin-Weller, Sonja Ständer, Andrew E. Pink, Brian M. Calimlim, Wan-Ju Lee, Henrique Teixeira, Barry Ladizinski, Xiaofei Hu, Yang Yang, Yingyi Liu, Meng Liu, Ayman Grada, Andrew M. Platt, Jonathan I. Silverberg
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 5, Pp 1127-1144 (2024)
Abstract Introduction Atopic dermatitis (AD) is characterized by intense itch and other symptoms that negatively impact quality of life (QoL). This study evaluates the effect of upadacitinib (an oral selective Janus kinase inhibitor) monotherapy on p
Externí odkaz:
https://doaj.org/article/d13086b1bc984adeabc8518d220ee7d9
Autor:
Esmé Kamphuis, Celeste M. Boesjes, Laura Loman, Marijke Kamsteeg, Inge Haeck, Anneke M.T. van Lynden-van Nes, Klaziena Politiek, Liana F. van der Gang, Marlies de Graaf, Marjolein S. de Bruin-Weller, Marie L.A. Schuttelaar
Publikováno v:
Acta Dermato-Venereologica, Vol 104 (2024)
Limited daily practice data on the effect of abrocitinib in patients with atopic dermatitis are available. The aim of this multicentre prospective study is to evaluate the effectiveness and safety of abrocitinib in patients with atopic dermatitis tre
Externí odkaz:
https://doaj.org/article/10c6bab35c064270bcdfd268403c0c5c
Autor:
Lisa P. van der Rijst, Annet van Royen-Kerkhof, Suzanne G. M. A. Pasmans, Renske Schappin, Marjolein S. de Bruin-Weller, Marlies de Graaf
Publikováno v:
Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Biologicals are becoming increasingly important in the therapeutic landscape of pediatric patients with moderate-to-severe atopic dermatitis (AD). Currently, dupilumab and tralokinumab are registered for the treatment of moderate-to-severe AD, and no
Externí odkaz:
https://doaj.org/article/ea6573b6f7824f078f432f45ebd3f7c7
Autor:
Lara S. van derSchoot, Hans J. M. M. Groenewoud, Marleen M. H. J. vanGelder, Marisol E. Otero, W. Peter Arnold, Maartje A. M. Berends, Marjolein S. De Bruin‐Weller, Sharon R. P. Dodemont, Marloes M. Kleinpenning, Marjolein I. A. Koetsier, Else N. Kop, John E. M. Körver, Astrid L. A. Kuijpers, Paula P. vanLümig, Johannes M. Mommers, Marcellus D. Njoo, Paul M. Ossenkoppele, Ron A. Tupker, M. Birgitte Visch, Lizelotte J. M. T. Weppner‐Parren, Elke M. G. J. deJong, Juul M. P. A. van denReek
Publikováno v:
JEADV Clinical Practice, Vol 1, Iss 3, Pp 240-253 (2022)
Abstract Background Limited real‐world studies are available comparing infection risk between biologics for psoriasis. Objectives The primary aim was to determine the differential effect of currently available biologics on the risk of respiratory t
Externí odkaz:
https://doaj.org/article/51346b81a8394876a681b2a06b4be13f
Autor:
Jart A. F. Oosterhaven, Lotte S. Spekhorst, Junfen Zhang, Angelique N. Voorberg, Geertruida L. E. Romeijn, Celeste M. Boesjes, Marlies de Graaf, Marjolein S. de Bruin-Weller, Marie L. A. Schuttelaar
Publikováno v:
Journal of Dermatological Treatment, Vol 33, Iss 4, Pp 1986-1989 (2022)
Background Eczema control is a new construct to be measured in atopic dermatitis (AD). Objectives Measuring patient-perceived eczema control and treatment satisfaction in AD patients, treated with dupilumab between 16 and 52 weeks. Methods Cross-sect
Externí odkaz:
https://doaj.org/article/c1409ece85b640d8a7c66a6f961ac68a
Autor:
Celeste M. Boesjes, Liana F. van der Gang, Nicolaas P.A. Zuithoff, Daphne S. Bakker, Lotte S. Spekhorst, Inge Haeck, Marijke Kamsteeg, Marlies de Graaf, Marjolein S. de Bruin-Weller
Publikováno v:
Acta Dermato-Venereologica, Vol 103 (2023)
Clinical trials showed that upadacitinib, a selective Janus kinase-1 inhibitor, is effective for treatment of moderate-to-severe atopic dermatitis. However, daily practice studies are limited. This multicentre prospective study evaluated the effectiv
Externí odkaz:
https://doaj.org/article/5bff64fc4629473ca94459edc68dcbcd
Autor:
Celeste M. Boesjes, Esmé Kamphuis, Nicolaas P.A. Zuithoff, Daphne S. Bakker, Laura Loman, Lotte S. Spekhorst, Inge Haeck, Marijke Kamsteeg, Anneke M.T. van Lynden-van Nes, Floor M. Garritsen, Klaziena Politiek, Marja Oldhoff, Marlies de Graaf, Marie L.A. Schuttelaar, Marjolein S. de Bruin-Weller
Publikováno v:
Acta Dermato-Venereologica, Vol 102 (2022)
Clinical trials have shown that baricitinib, an oral selective Janus kinase 1/2 inhibitor, is effective for the treatment of moderate-to-severe atopic dermatitis. However, daily practice data are limited. Therefore, this multicentre prospective study
Externí odkaz:
https://doaj.org/article/6dc30f1fc5984ffba05ccf16d2397936
Autor:
Marloes E. van Muijen, Sarah E. Thomas, Hans M.M. Groenewoud, Marisol E. Otero, Paul M. Ossenkoppele, Marcellus D. Njoo, Sharon R.P. Dodemont, Else N. Kop, Maartje A.M. Berends, Marjolein I.A. Koetsier, Johannes M. Mommers, John E.M. Körver, Ron A. Tupker, Marjolein S. de Bruin-Weller, Lizelotte J.M.T. Weppner-Parren, Bas Peters, Marloes M. Kleinpenning, Astrid L.A. Kuijpers, W. Peter Arnold, Paula P.M. van Lümig, Juul M.P.A. van den Reek, Elke M.G.J. de Jong
Publikováno v:
Acta Dermato-Venereologica, Vol 102 (2022)
Real-world evidence, directly comparing the effectiveness of interleukin (IL)17-inhibitors, IL23-inhibitors, tumour necrosis factor alpha (TNF-α)-inhibitors and an IL12/23-inhibitor in psoriasis, is scarce. The aim of this study was to directly comp
Externí odkaz:
https://doaj.org/article/e146b3b81ecf4e69ba49684069d330cc
Autor:
Jonathan I. Silverberg, Eric L. Simpson, Mark Boguniewicz, Marjolein S. De Bruin-Weller, Peter Foley, Yoko Kataoka, Gaëlle Bégo-Le-Bagousse, Zhen Chen, Brad Shumel, Jingdong Chao, Ana B. Rossi
Publikováno v:
Acta Dermato-Venereologica, Vol 101, Iss 11 (2021)
Optimal management of atopic dermatitis requires a comprehensive assessment of response to treatment in order to inform therapeutic decisions. In a real-world setting, successful response to atopic dermatitis treatment is measured by sustained improv
Externí odkaz:
https://doaj.org/article/533ab1ccbbd94b2b91b12b77601f1e28
Autor:
Lieneke F.M. Ariëns, Daphne S. Bakker, Lotte S. Spekhorst, Jorien van der Schaft, Judith L. Thijs, Inge Haeck, Annebeth E. Flinterman, Marijke Kamsteeg, Marie L.A. Schuttelaar, Marjolein S. De Bruin-Weller
Publikováno v:
Acta Dermato-Venereologica, Vol 101, Iss 10 (2021)
Dupilumab treatment improves signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis. This study evaluated the impact of dupilumab treatment on absenteeism, presenteeism, and related costs in a large multi-centre co
Externí odkaz:
https://doaj.org/article/8aae7890d16745a0940feeb193d54262